New MS drug shows promise in Head-to-Head trial against standard therapies
NCT ID NCT04788615
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 29 times
Summary
This study tested a monthly injection of ofatumumab against other standard first-line medications for people newly diagnosed with relapsing multiple sclerosis (MS). The goal was to see which treatment better controls disease activity without relapses, new brain lesions, or worsening disability. 185 adults aged 18-55 took part, and the results help doctors choose the best initial therapy for MS.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Bayonne, Bayonne Cedex, 64109, France
-
Novartis Investigative Site
Amiens, 80054, France
-
Novartis Investigative Site
Bordeaux, 33076, France
-
Novartis Investigative Site
Clermont-Ferrand, 63003, France
-
Novartis Investigative Site
Créteil, 94010, France
-
Novartis Investigative Site
Gonesse, 95500, France
-
Novartis Investigative Site
Grenoble, 38043, France
-
Novartis Investigative Site
Montpellier, 34090, France
-
Novartis Investigative Site
Nice, 06202, France
-
Novartis Investigative Site
Nîmes, 30029, France
-
Novartis Investigative Site
Poissy, 78303, France
-
Novartis Investigative Site
Rennes, 35033, France
-
Novartis Investigative Site
Strasbourg, 67000, France
-
Novartis Investigative Site
Frankfurt am Main, Hesse, 60590, Germany
-
Novartis Investigative Site
Westerstede, Lower Saxony, 26655, Germany
-
Novartis Investigative Site
Cologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
Bayreuth, 95445, Germany
-
Novartis Investigative Site
Berlin, 12101, Germany
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Bielefeld, 33647, Germany
-
Novartis Investigative Site
Dortmund, 44137, Germany
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Siegen, 57076, Germany
-
Novartis Investigative Site
Ulm, 89073, Germany
-
Novartis Investigative Site
Montichiari, BS, 25018, Italy
-
Novartis Investigative Site
Milan, MI, 20132, Italy
-
Novartis Investigative Site
Roma, RM, 00133, Italy
-
Novartis Investigative Site
Roma, RM, 00189, Italy
-
Novartis Investigative Site
Orbassano, TO, 10043, Italy
-
Novartis Investigative Site
Naples, 80131, Italy
-
Novartis Investigative Site
Santiago Compostela, A Coruna, 15706, Spain
-
Novartis Investigative Site
Salt, Girona, 17190, Spain
-
Novartis Investigative Site
El Palmar, Murcia, 30120, Spain
-
Novartis Investigative Site
Barakaldo, Vizcaya, 48903, Spain
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Madrid, 28040, Spain
-
Novartis Investigative Site
Málaga, 29010, Spain
-
Novartis Investigative Site
Seville, 41009, Spain
-
Novartis Investigative Site
Valencia, 46026, Spain
Conditions
Explore the condition pages connected to this study.